dihexa clinical trial 2025 D I H E X A is having a moment right now… and I get why. When something gets labeled as “brain repair” or “synapse growth,” it spreads FAST especially in communities Dihexa (PNB-0408) | c-Met/HGFR Activator

Cognitive behavioural therapy for insomnia remains a recognised first-line approach in current evidence-based care

That approval status is a hard regulatory fact, and it is the single biggest reason a CagriSema-versus-tirzepatide comparison is not a comparison of equals: one product has cleared a full regulatory efficacy-and-safety review, and the other has not yet

Cells 18 ChangL.HuY.FuY.ZhouT.YouJ.DuJ.et al (2019)

It means the better fit depends on what kind of recovery question someone is trying to solve

NCT04982575

The overall impression from available evidence is that DSIP appears reasonably well-tolerated with a low incidence of serious adverse effects in the populations and contexts studied, but significant gaps in safety knowledge remain, particularly regarding long-term use, use in specific populations (elderly, children, those with comorbidities), and comprehensive toxicology assessment meeting modern pharmaceutical standards